文献速递脑血管病

新型神经活性甾体前药NTS-104的药理学特征及其在实验性卒中模型中的神经保护活性

Pharmacological Characterization of a Novel Neuroactive Steroid Prodrug, NTS-104, and Its Neuroprotective Activity in Experimental Stroke Models.
PubMed 文献 · Stroke · 2022-09-27

研究在大鼠缺血性卒中模型中探究了NTS-104(NTS-105的前药)的药代动力学、药效学及疗效。NTS-104给药后迅速转化为NTS-105,在栓塞性和短暂性大脑中动脉闭塞模型中,缺血后4小时给药可剂量依赖性地改善神经功能结局并缩小梗死体积,同时调节缺血脑内AKT活化及细胞因子水平。

要点

  • NTS-104给药后快速转化为NTS-105,约1小时达峰浓度,在正常脑和缺血脑分布相似。
  • 栓塞性大脑中动脉闭塞后4小时给予NTS-104,可剂量依赖性地改善神经功能并缩小梗死体积。
  • 短暂性大脑中动脉闭塞后4小时给予NTS-104单剂量也具神经保护作用,并降低IL-6、VEGF等多种因子。

核心结论

  • NTS-104是一种新型前药,转化为新型神经活性甾体NTS-105,在实验性缺血性卒中模型中改善功能结局。

研究设计与样本

  • 在未卒中和卒中大鼠中研究NTS-104/105的药效学与药代动力学,采用栓塞性和短暂性大脑中动脉闭塞模型探究NTS-104的剂量相关效应。
  • 所有大鼠随机分配至实验组,所有结局测量均盲法进行。

主要发现

  • 血浆和脑药代动力学分析显示NTS-104迅速转化为NTS-105,约1小时达峰浓度,在正常脑和缺血脑分布相似。
  • 栓塞性大脑中动脉闭塞后4小时给予NTS-104,相对溶媒对照组剂量依赖性改善神经功能结局并剂量依赖性缩小梗死体积。
  • 短暂性大脑中动脉闭塞后4小时给予NTS-104的单剂量水平研究证实其也具有神经保护作用。
  • 定量ELISA显示NTS-104治疗导致缺血脑内AKT活化和细胞因子水平呈时间和剂量依赖性变化,包括IL-6、VEGF、ICAM-1、IL-1β、MCP-1、RAGE和GM-CSF降低。
  • 血浆中IL-6和GM-CSF呈时间和剂量依赖性降低,同时半乳糖凝集素-1升高。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Ischemic stroke affects about 700 000 patients per year in the United States, and to date, there are no effective pharmacological agents that promote recovery. Here, we studied the pharmacokinetics, pharmacodynamics, and efficacy of NTS-105, a novel neuroactive steroid, and NTS-104, a prodrug of NTS-105, in 2 models of ischemic stroke. METHODS: The pharmacodynamics and pharmacokinetics of NTS-104/105 were investigated in naive and stroke rats, and models of embolic and transient middle cerebral artery occlusion were used to investigate the dose-related effects of NTS-104. All rats were randomly assigned into the experimental groups, and all outcome measurements were performed blindly. RESULTS: Blood plasma and brain pharmacokinetic analysis revealed that NTS-104 rapidly converted to NTS-105, which reached peak concentration at ≈1 hour after dosing and distributed similarly to normal and ischemic brains. NTS-104 administration 4 hours after embolic middle cerebral artery occlusion led to a dose-dependent improvement of neurological outcomes and a dose-dependent reduction of infarct volumes relative to vehicle-treated animals. A single dose level study confirmed that NTS-104 administered 4 hours after transient middle cerebral artery occlusion was also neuroprotective. Quantitative ELISA revealed that NTS-104 treatment resulted in time- and dose-dependent changes in AKT activation and cytokine levels within the ischemic brain, which included reductions of IL-6, VEGF, ICAM-1, IL-1β, MCP-1, RAGE, and GM-CSF. Time- and dose-dependent reductions in IL-6 and GM-CSF were also observed in the plasma along with an elevation of galectin-1. CONCLUSIONS: NTS-104 is a novel prodrug that converts to a novel neuroactive steroid, NTS-105, which improves functional outcomes in experimental ischemic stroke models.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Zhang L, Schwartz-Byrne R, Gertz S, et al. Pharmacological Characterization of a Novel Neuroactive Steroid Prodrug, NTS-104, and Its Neuroprotective Activity in Experimental Stroke Models. Stroke. 2022. PMID: 36168130. doi:10.1161/STROKEAHA.122.038507

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。